{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:05:17Z","timestamp":1761588317955,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110374","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T23:28:12Z","timestamp":1684884492000},"page":"110374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cyclophosphamide with cyclosporine A for graft-versus-host disease prophylaxis in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation from human leucocyte antigen-matched donors"],"prefix":"10.1016","volume":"120","author":[{"given":"Mustafa O.","family":"Sharaf El-Deen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-9385","authenticated-orcid":false,"given":"Moetaza M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Al-Azab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Samra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-2852","authenticated-orcid":false,"given":"Mohammad E.E.","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2021","series-title":"Hematopoietic stem cell transplantation","author":"Khaddour","key":"10.1016\/j.intimp.2023.110374_b0005"},{"issue":"9","key":"10.1016\/j.intimp.2023.110374_b0010","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic Graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2023.110374_b0015","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110374_b0020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V67.4.1172.1172","article-title":"Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation","volume":"67","author":"Sullivan","year":"1986","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.intimp.2023.110374_b0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2023.110374_b0030","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","article-title":"Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups","volume":"97","author":"Bacigalupo","year":"2012","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.intimp.2023.110374_b0035","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.intimp.2023.110374_b0040","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2023.110374_b0045","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor\u2013free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"25","key":"10.1016\/j.intimp.2023.110374_b0050","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110374_b0055","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2023.110374_b0060","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.bbmt.2012.06.014","article-title":"Graft-versus-host disease induced graft-versus-leukemia effect: Greater impact on relapse and disease-free survival after reduced intensity conditioning","volume":"18","author":"Weisdorf","year":"2012","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"10","key":"10.1016\/j.intimp.2023.110374_b0065","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0070","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2023.110374_b0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"16","key":"10.1016\/j.intimp.2023.110374_b0080","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.intimp.2023.110374_b0085","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius","volume":"117","author":"Socie","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2023.110374_b0090","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.intimp.2023.110374_b0095","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2023.110374_b0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: One size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2023.110374_b0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.intimp.2023.110374_b0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"3","key":"10.1016\/j.intimp.2023.110374_b0115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"7","key":"10.1016\/j.intimp.2023.110374_b0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1703389","article-title":"Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation","volume":"29","author":"Wolff","year":"2002","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2023.110374_b0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/bjh.14190","article-title":"Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients","volume":"175","author":"Teltschik","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110374_b0130","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2023.110374_b0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.clml.2020.04.021","article-title":"The Use of Post-transplantation cyclophosphamide in peripheral blood HLA-matched stem cell transplantation as graft-versus-host disease prophylaxis in Patients With malignant or non-malignant hematologic disorders: A single-center experience of 52 patients","volume":"20","author":"Mahmoud","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.intimp.2023.110374_b0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"29","key":"10.1016\/j.intimp.2023.110374_b0145","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110374_b0150","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2023.110374_b0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2016.12.636","article-title":"Post-transplant cyclophosphamide and tacrolimus-Mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors","volume":"23","author":"Carnevale-Schianca","year":"2017","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"11","key":"10.1016\/j.intimp.2023.110374_b0160","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","article-title":"Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation","volume":"128","author":"Greco","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0165","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.2022.281256","article-title":"Post-transplant cyclophosphamide: Overcoming the HLA barrier to hematopoietic stem cell transplants","volume":"107","author":"Bacigalupo","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2023.110374_b0170","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5(211):211ra157","author":"Kanakry","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0175","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2023.110374_b0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaccao.2021.04.004","article-title":"Post-transplantation cyclophosphamide: An old nemesis to a new transplant paradigm?","volume":"3","author":"Rotz","year":"2021","journal-title":"JACC CardioOncology."},{"issue":"1","key":"10.1016\/j.intimp.2023.110374_b0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","article-title":"Post-transplant cyclophosphamide use in matched HLA donors: A review of literature and future application","volume":"55","author":"El Fakih","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0190","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0195","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A Modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: A multicenter study","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"10","key":"10.1016\/j.intimp.2023.110374_b0200","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: A comparative study on behalf of the acute leukemia working party of the european society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"6","key":"10.1016\/j.intimp.2023.110374_b0205","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bbmt.2016.02.018","article-title":"Recovery of unrelated donors of peripheral blood stem cells versus recovery of unrelated donors of bone Marrow: A prespecified analysis from the phase III blood and marrow transplant clinical trials network protocol 0201","volume":"22","author":"Burns","year":"2016","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation."},{"issue":"16","key":"10.1016\/j.intimp.2023.110374_b0210","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","article-title":"Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis","volume":"19","author":"Cutler","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110374_b0215","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"The Lancet Haematology."},{"issue":"4","key":"10.1016\/j.intimp.2023.110374_b0220","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: Impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transplant."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:00:39Z","timestamp":1761588039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":44,"alternative-id":["S1567576923006975"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110374","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide with cyclosporine A for graft-versus-host disease prophylaxis in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation from human leucocyte antigen-matched donors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110374"}}